Truist Financial Has Lowered Expectations for Teleflex (NYSE:TFX) Stock Price

Teleflex (NYSE:TFX) had its price objective dropped by stock analysts at Truist Financial from $128.00 to $120.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “hold” rating on the medical technology company’s stock. Truist Financial’s price target would suggest a potential upside of 11.92% from the company’s previous close.

TFX has been the subject of several other research reports. Royal Bank Of Canada lowered their price target on shares of Teleflex from $135.00 to $120.00 and set a “sector perform” rating for the company in a research report on Friday. Mizuho raised their target price on Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. Wells Fargo & Company lowered their price target on Teleflex from $131.00 to $114.00 and set an “equal weight” rating on the stock in a report on Friday. Zacks Research lowered shares of Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Teleflex in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $134.57.

Teleflex Stock Performance

Shares of NYSE TFX traded down $2.18 during midday trading on Monday, hitting $107.22. The company’s stock had a trading volume of 211,112 shares, compared to its average volume of 741,217. The firm has a market cap of $4.74 billion, a P/E ratio of 25.24, a P/E/G ratio of 1.79 and a beta of 1.05. Teleflex has a 1-year low of $102.58 and a 1-year high of $200.15. The firm’s fifty day moving average price is $125.66 and its 200-day moving average price is $123.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, November 6th. The medical technology company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.38 by $0.29. The company had revenue of $892.90 million during the quarter, compared to analyst estimates of $892.79 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The business’s revenue was up 19.4% compared to the same quarter last year. During the same period in the prior year, the company earned $3.49 earnings per share. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. On average, sell-side analysts forecast that Teleflex will post 13.98 EPS for the current fiscal year.

Institutional Trading of Teleflex

A number of hedge funds have recently bought and sold shares of TFX. Brown Advisory Inc. increased its position in shares of Teleflex by 34.2% in the first quarter. Brown Advisory Inc. now owns 2,524 shares of the medical technology company’s stock worth $349,000 after acquiring an additional 643 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of Teleflex by 504.8% in the first quarter. Allworth Financial LP now owns 254 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 212 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Teleflex by 5.1% in the first quarter. New York State Common Retirement Fund now owns 25,639 shares of the medical technology company’s stock worth $3,543,000 after buying an additional 1,239 shares during the period. Louisiana State Employees Retirement System grew its holdings in shares of Teleflex by 776.0% during the first quarter. Louisiana State Employees Retirement System now owns 21,900 shares of the medical technology company’s stock valued at $3,026,000 after buying an additional 19,400 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its position in Teleflex by 47.8% during the first quarter. Rice Hall James & Associates LLC now owns 4,764 shares of the medical technology company’s stock valued at $658,000 after buying an additional 1,540 shares during the period. 95.62% of the stock is owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.